Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$5.03 USD
-0.04 (-0.79%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $5.02 -0.01 (-0.20%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Vir Biotechnology, Inc. has a market cap of $700.87M, which represents its share price of $5.07 multiplied by its outstanding shares number of 138.24M. As a small-cap company, VIR's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VIR 5.03 -0.04(-0.79%)
Will VIR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIR
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
VIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
Other News for VIR
Vir Biotechnology (VIR) Begins Phase 3 Trial for Hepatitis Delta Treatment
Vir Biotechnology enrolls first patient in ECLIPSE trial
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program ...
Vir Biotechnology (VIR) Begins Phase 1 Trial for New Cancer Treatment | VIR Stock News
Vir Biotechnology doses first patient in VIR-5525 trial